Standard BioTools to sell Microfluidics business to ARCHIMED; close expected in ~30 days

STANDARD BIOTOOLS INC.

Standard BioTools (NASDAQ: LAB) signed a definitive agreement to sell its Microfluidics business to ARCHIMED, a healthcare-focused investment firm; closing expected in approximately 30 days.
No purchase price, revenue multiple, or other financial terms for the Microfluidics sale were disclosed in the press release.
CEO Michael Egholm called it 'a strong outcome for our employees and our customers' and 'another important step in the strategic actions we laid out' for shareholders.
Microfluidics will keep operating as part of Standard BioTools until closing; the deal is subject to customary closing conditions.
Separately pending: a merger with Treeline Biosciences (Form S-4 preliminary proxy filed July 20, 2026) and a sale of the Mass Cytometry unit to Element Biosystems.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.